Today: 15.Oct.2018
EANM prostate cancer radium 223 (European Association of Nuclear Medicine) Austria Europe
21.Jul.2017
Rate this item
(0 votes)

European Association of Nuclear Medicine: At an advanced stage prostate cancer frequently leads to bone metastases which may result in pain, fractures, and disability and are associated with a poor prognosis. Recently a major breakthrough has been achieved which is about to improve the patients’ situation, as Prof. Markus Luster, expert of the European Association of Nuclear Medicine (EANM), points out: “Radium-223- dichloride is the first bone-targeted drug that not only alleviates symptoms but also prolongs the life expectancy of these patients.

Read 441 times Last modified on Thursday, 12 October 2017 12:57

Newsletter Subscription

  • Latest
  • Popular
  • Rob Jeffrey, Economic Risk Consultant, Poverty is…
  • Mohn Doss, Medical Physicist in Diagnostic Imaging:…
  • John Dunn, MD, JD: The United States…
  • Robert Bryce is author of “Smaller Faster…
  • Leon Louw, lawyer, economist, Executive Director of…